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Abstract 
Obstructive sleep apnoea (OSA) is very common in patients with Type 2 diabetes (T2D), which is not 
surprising considering that obesity is a common risk factor for both conditions. In general population 
studies, OSA has been shown to be associated with several comorbidities including increased risk of 
road traffic accidents, T2D, hypertension and lack of nocturnal dipping of blood pressure, 
hyperlipidaemia, increased inflammation, increased risk of cardiovascular disease and mortality, 
increased risk of atrial fibrillation, worse quality of life, and erectile dysfunction. However, the 
impact of OSA on diabetes-related vascular and metabolic outcomes remains unclear. Furthermore, 
the impact of continuous positive airway pressure (CPAP) treatment in patients with T2D is also 
unclear.  This unclarity regarding the impact of OSA and CPAP in patients with T2D has possibly 
contributed to the lack of screening for OSA in patients with T2D in the UK despite the high 
prevalence of OSA in patients with T2D. In this commentary, I provide an overview about OSA with a 
particular focus on its role and impact in patients with T2D. 
Introduction 
Obstructive sleep apnoea (OSA) is a common medical disorder. While earlier estimates suggested a 
4% prevalence in men and 2% prevalence in women, more recent studies indicate a prevalence of 
17–26% of men and 9–28% of women1. This increase in OSA prevalence is likely to reflect the global 
increase in obesity, which is a major risk factor of OSA2;3, and/or may reflect higher awareness of this 
condition leading to increased diagnosis.  
As obesity is a common risk factor for OSA and Type 2 diabetes (T2D), it is not surprising that these 
conditions commonly co-exist2;4. The prevalence of OSA is high in people with T2D (8.5–86%, with 
23.8–70% for moderate-to-severe OSA)3-10; the variation in OSA prevalence between studies is due 
to multiple factors including differences in studies populations (for example primary care vs. 
secondary care), the methods of diagnosing OSA (polysomnography vs. portable devices), and the 
criteria used to diagnose OSA (apnoea hypopnea index (AHI) of 5 vs. 10 vs. 15 or using the oxygen 
desaturations index rather than AHI). Similarly, the prevalence of T2D is high patients with OSA (15-
30%)11. As a result, the International Diabetes federation (IDF) recommended in 2008 routine 
screening for OSA in patients with T2D,12 but despite the IDF statement a recent survey in the UK 
showed that two-thirds of diabetes healthcare professionals were unaware of these 
recommendations and only 19% had the local diabetes guidelines incorporated assessment for OSA 
in those at risk13.  
This lack of OSA screening in patients with T2D might be related to the reduced awareness of the 
associations between OSA and T2D, and might also reflect the lack of clear screening strategies and 
clinical pathways that inform practicing clinicians who to screen, how to screen, what to do after 
screening and how often to screen. Screening for OSA is further complicated by the fact that many 
of the symptoms that can be attributed to OSA can also be attributed to diabetes (see below), which 
makes identifying patients purely on clinical grounds more difficult.  Furthermore, there is lack of 
data regarding the clinical, metabolic and economic impacts of OSA in patients with T2D, the cost 
effectiveness of OSA screening and treatment in diabetes and the impact of OSA treatment on 
diabetes-related outcomes; these issues can make it difficult to justify routine screening for OSA14. 
OSA overview 
OSA is characterised by upper airway instability during sleep which results in recurrent episodes of 
complete or partial upper airway obstruction that leads to recurrent episodes of either complete 
(apnoea) or partial (hypopnea) cessation of airflow15. These apnoea and hypopnea events usually 
result in altered intrathoracic pressure and increased breathing efforts as the patient attempts to 
breath against a blocked upper airway; this leads to a brief awakening (microarousal) and 
restoration of upper airway patency with termination of the apnoea/hypopnea event2;4. Following 
restoration of upper airway patency, the same cycle of events will repeat itself resulting in recurrent 
oxygen desaturations. These cyclical changes in intra-thoracic pressure and recurrent microarousals 
result in sleep fragmentation and disruption of sleep architecture (loss of deep sleep and rapid eye 
movement (REM) sleep), which in part contribute to the excessive daytime sleepiness (EDS) 
observed in patients with OSA15. In addition to the above-mentioned changes, the apnoea/hypopnea 
events are frequently associated with cyclical changes in blood pressure (BP), heart rate and 
sympathetic activity15.  
Polysomnography (that typically records 12-16 channels) remains the gold standard for diagnosing 
OSA15. However, as polysomnography is time-consuming, resourceful, expensive and requires a 
hospital stay overnight, other alternatives have been developed. Portable home-based cardio-
respiratory Type III devices (typically recording 4-7 channels) are widely used in clinical practice as 
well as research, and their use is supported by the latest statement from the American Academy of 
Sleep Medicine (AASM)16. Type III portable devices have a sensitivity and specificity of 87-96% and 
60-76% respectively to diagnose OSA defined apnoea hypopnea index (AHI) ≥ 5 events/hour and 49-
92% and 79-95% respectively for OSA diagnosed as AHI ≥ 15 events/hour17. 
Clinically, OSA is associated with a variety of non-specific symptoms. Snoring is the most common 
symptom, occurring in 95% of patients with only 6% of OSA patients (or their partners) not reporting 
any snoring. However, it has a poor positive predictive value due to the high prevalence of snorers 
who don’t have OSA15. Witnessed apnoeas  can be reported by the partner but they do not correlate 
with disease severity and can occur in up to 6% of the “normal” population without OSA15. EDS is 
another important feature of OSA, but many OSA patients do not suffer from EDS, at least if 
measured using the Epworth Sleepiness Scale (ESS). Other OSA symptoms include choking, insomnia, 
nocturia, sweating, fatigue, morning headaches, erectile dysfunction and autonomic symptoms15;18. 
However, many of the above-mentioned OSA-related symptoms are either common in patients 
without OSA or can be attributed to a diabetes-related cause such as hyperglycaemia, 
hypoglycaemia, diabetic neuropathy, cardiovascular disease (CVD) or drug-related adverse events, 
which makes it difficult to suspect OSA on clinical grounds only in patients with T2D. 
OSA is associated with several comorbidities including increased risk of road traffic accidents, 
incipient hypertension and lack of nocturnal dipping of BP, hyperlipidaemia, increased inflammation, 
increased risk of CVD and mortality, increased risk of atrial fibrillation, worse quality of life, and 
erectile dysfunction1;10;17;19-28. 
Continuous positive airway pressure (CPAP) is the mainstay treatment for moderate to severe OSA. 
CPAP usage for ≥ 4 hours/night resulted in reduction of the risk of road traffic accidents29. In a recent 
meta-analysis of randomised controlled trials (RCTs) CPAP (compared to sham) was associated with 
reduction of AHI (WMD, -33.8, 95% CI -42.0 to -25.6); ESS (-2.0, 95% CI -2.6 to -1.4); diurnal systolic 
BP (-2.4, 95% CI -3.9 to -0.9) and diurnal diastolic BP (-1.3, 95% CI -2.2 to -0.4) and improved quality 
of life17. One RCT showed that 4 weeks of CPAP improved cognitive function following a stroke 
compared rehabilitation treatment30. Lifestyle and dietary interventions and the use of mandibular 
advancement devices were also associated with significant improvements in AHI and ESS but the 
effect sizes were smaller than CPAP17;31. Bariatric surgery has also been shown to result in a 
significant reduction in AHI (weighted decrease 29/h; 95%CI 22.41 to 36.74)32. Despite the a 
favourable impact of CPAP on BP and erectile dysfunction when compared to placebo, it was less 
efficacious in treating erectile dysfunction and hypertension than sildenafil33-36 and valsartan37, 
respectively.  
It must be emphasised, that while CPAP is the “gold-standard” treatment for patients with OSA in 
terms of the impact on AHI and EDS, weight loss also has a major role, particularly as it reduces CVD 
while the evidence for CPAP in altering vascular events is based on observational studies rather than 
RCTs. In addition, the combination of CPAP and weight loss has been shown to have greater impact 
on some cardiovascular risk factors compared to CPAP alone38;39. 
In the UK, NICE recommended the use CPAP in patients with moderate to severe OSA with EDS 
(https://www.nice.org.uk/guidance/ta139/chapter/1-Guidance); but despite NICE guidance the 
availability and delivery of OSA services vary considerably across the UK   
(https://www.blf.org.uk/sites/default/files/OSA_Toolkit_2015_BLF_0.pdf). 
OSA and T2D: A chicken and egg?  
As highlighted above, OSA and T2D commonly co-exist but is there a causative relationship between 
the two conditions and, if so, which one comes first? Most of the literature is focussed on examining 
the impact of OSA on incident T2D. Indeed, several longitudinal studies and meta-analyses have 
shown that OSA is a risk factor for the development of T2D independent of obesity and other 
traditional risk factors (RR 1.4-1.63 depending on the study)2;10;40;41. It is plausible that OSA can lead 
to the development of T2D as OSA is associated with insulin resistance and β-cell dysfunction; this 
relationship is mediated by several neurohormonal and inflammatory mechanisms and increased 
oxidative stress2;10;42. However, whether CPAP treatment might reduce the incidence of T2D is 
awaiting the results of ongoing RCTs but early evidence suggests potential benefit. In one recent 
RCT, 8 hours of CPAP reduced the area under the curve for the 2-h overall glucose response during 
OGTT compared to placebo and improved insulin sensitivity, 24-h BP and norepinephrine levels43. 
Nonetheless, this study was small (n=39), of short duration (2 weeks) and was conducted in 
laboratory environment to ensure high compliance with CPAP under direct supervision which might 
prove difficult to achieve in real life. In another RCT in patients with severe OSA but without 
diabetes, CPAP for 12 weeks reversed impaired glucose tolerance in 9/42 patients vs. 5/38 patients 
in the life style counselling group (p=0.039) without any changes in weight or HOMA-IR44. In another 
observational study, the incidence of T2D over a median of 5 months was lower in patients who had 
outstanding (≥ 90% of nights and 8 h/night), excellent (≥ 80% nights and ≥ 6 h/night) and good (≥ 
70% nights and ≥ 4 h/night) compliance with CPAP compared to those who were non-adherent to 
CPAP (0%, 0%,  0.8%, and 4% respectively)45. The impact of OSA on dysglycaemia, insulin resistance 
and beta-cell dysfunction is mediated by multiple mechanisms including increased oxidative stress, 
sympathetic overactivity, activation of the hypothalamic pituitary adrenal access, increased 
inflammation and adipokine changes; most of which is improved by CPAP42. 
On the other hand, it is also plausible that T2D might also be a risk factor for OSA or worsening of 
pre-existing OSA, but this has not been explored widely in the literature. One longitudinal study 
showed that baseline HOMA-IR was an independent predictor of incident witnessed apnoeas (OR 
1.31, 95%CI 1.13–1.51) after adjustment for age, sex, and waist circumference over 6 years period46. 
Other independent predictors of witnessed sleep apnoeas included waist circumference, 
triglycerides levels and smoking 46. All these factors are common in patients with T2D and hence 
might increase the risk of developing apnoeas and OSA in patients with T2D. In addition, the weight 
gain that occur in patients with T2D with treatment intensification might result in the development 
of, or worsening of pre-existing, OSA47-49, while weight loss in patients with T2D improved AHI in a 
longitudinal study50. Furthermore, the development of autonomic neuropathy in patients with T2D 
might have an impact on upper airway innervation and collapsibility, ventilatory drive and central 
respiratory centre responses to hypercapnic stimulus, all of which contribute to the pathogenesis of 
OSA51;52. 
It is likely that the relationship between OSA and T2D is bidirectional and that each of these 
conditions can contribute to the development or worsening of the other. However, understanding 
this complex relationship is important to develop the appropriate screening and treatment 
strategies. While both conditions (OSA and T2D) are associated with similar comorbidities (such as 
hypertension, CVD, hyperlipidaemia, chronic kidney disease (CKD) etc.), whether the impact of 
having both conditions (i.e. OSA and T2D) on CVD and other comorbidities is greater than having 
either OSA or T2D alone is the focus of several ongoing studies. In addition, the impact of OSA on the 
above-mentioned comorbidities in patients with T2D might differ whether OSA was present before 
or developed after the onset of T2D. In OSA patients who subsequently develop T2D, it is possible 
that the combination of OSA and T2D results in greater impact on diabetes-related outcomes and 
intervention targeting OSA might produce larger benefits as the diabetes-related comorbidities are 
still at earlier stages of development with the potential of reversibility. On the other hand, if OSA 
developed after the onset of diabetes, then targeting OSA might produce less effects as many 
complications have already been established and therefore less likely to reverse. However, these 
hypotheses remain to be examined and explored in ongoing studies and trials. 
OSA and glycaemic control in T2D 
OSA has been linked to worse glycaemic measures (such as HbA1c, fasting plasma glucose or glucose 
variability) following adjustment for a wide range of confounders in several cross-sectional 
studies2;4;53. However, though biologically plausible, causality between OSA and worse glycaemic 
control has not been proven as yet due to the lack of longitudinal studies and the conflicting results 
of clinical trials. The impact of OSA on HbA1c ranged between 0.7 to 3.69%; this variation between 
studies is likely to be due to methodological differences and variability in OSA severity between 
studies2;4;53. 
Overall, uncontrolled studies of short duration (≤ 4 months) showed that CPAP improved glycaemic 
variability, postprandial glucose levels and HbA1c in patients with T2D but RCTs did not overall show 
such benefits2;4;53. In a small RCT of 42 men with T2D and OSA who were randomized to CPAP vs. 
sham CPAP, three months of treatment did not show any impact of CPAP on HbA1c but CPAP 
compliance was poor, preventing definitive conclusions 54. In a more recent study of patients with 
T2D and moderate to severe OSA in which 298 patients were randomised to CPAP vs. usual care, 
CPAP again failed to show an impact on HbA1c but glucose control was fairly good at baseline 
(HbA1c 7.3%), which may have contributed to the negative findings 55. In contrast, another RCT in 
which 50 patients with T2D and OSA were randomised to CPAP vs. no CPAP for 6 months, CPAP 
resulted in greater HbA1c reductions compared to no CPAP (between group adjusted difference -
0.4% (95%CI -0.7 to -0.04, p=0.029). Of note, the compliance in this study was good with average 
CPAP usage of 5.2 hours per night56. The conflicting results of these studies might be related to 
multiple factors included differences in CPAP compliance, baseline glycaemic control and the reserve 
in β-cell function. Other factors related to OSA might also play an important part; for example some 
studies showed that the impact of CPAP might be greater in patients with OSA and EDS vs. OSA but 
not EDS57, whereas others showed that the relation between OSA and glycaemic measures mainly 
relate to apnoea/hypopnea events that occur in REM sleep compared to non-REM sleep58. Further 
large RCTs that will include patients in the early stages of T2D and that consider factors such as EDS 
and REM-related AHI and in which CPAP compliance is high are still needed to answer the question 
whether CPAP treatment improves glycaemic control in patients with T2D. 
OSA and hypertension (Table 1) 
Epidemiological studies and RCTs have shown a causal link between OSA and incident hypertension 
and non-dipping BP and that CPAP lowered BP compared to no CPAP or sham CPAP but the impact 
of CPAP was less than that of valsartan in one RCT21;37;59. However, data in patients with T2D are 
limited. In an observational retrospective cohort study in patients with OSA and T2D, CPAP was 
associated with improvements in systolic (-6.81, 95%CI -9.94 to -3.67 mmHg) and diastolic (-3.69, 
95%CI -5.53 to -1.85 mmHg) BP over 9-12 months period60. Similar reductions in BP levels were 
found after 3 months of CPAP in a RCT in which patients were randomised to early (<1 week) or late 
(1–2 months)61 intervention. 
OSA and cardiovascular disease (Table 1) 
In general population studies, several cross-sectional and longitudinal studies showed a link between 
OSA and CVD. Based on intravascular ultrasound and CT coronary angiogram, OSA and AHI were 
found to be associated with a larger atherosclerotic plaque volume62;63.  In addition, a study found a 
diurnal variation in the occurrence of acute myocardial infarction in that patients with OSA were at 
increased risk of acute myocardial infarction overnight (midnight to 6am) compared to those 
without OSA, suggesting a possible role for the nocturnal OSA-associated events in the development 
of CVD64. Longitudinal observational studies have shown increase risk of incident CVD and mortality 
in patients with OSA compared to those without OSA over 3–10 years (adjusted OR/HR for incident 
CVD of 1.97–4.9) and that CPAP treatment was associated with lower vascular events and 
mortality22-24;65-69. While this looks encouraging, there is no evidence from RCTs that CPAP lowered 
mortality or CVD17;70;71. However, most these RCTs were ≤12 weeks duration and only one showed a 
follow up of more than 1 year; therefore and the number of vascular events and mortality was small. 
Data regarding the impact of OSA on CVD in diabetes are rather limited. In the SleepAhead study, 
AHI was associated with history of stroke (adjusted OR 2.57, 95% CI 1.03–6.42), but not coronary 
artery disease72. OSA was found to predict incident coronary artery disease (adjusted HR 2.2, 95% CI 
1.2–3.9, p=0.01) and heart failure (adjusted HR 3.5, 95 % CI 1.4–9.0; p<0.01) in 132 patients with T2D 
and a normal baseline exercise echocardiography test over a median follow-up of 4.9 years73.  It 
remains unclear, however, whether treating OSA in these patients alters vascular outcome or heart 
failure in this high-risk population. 
OSA and microvascular complications in T2D (Table 1) 
OSA shares many of its molecular consequences with hyperglycaemia which can lead to 
microvascular complications in patients with T2D. OSA can result in increased oxidative stress and 
nitrosative stress, Poly (ADP-ribose) polymerase (PARP) activation, increased advanced glycation 
end-products (AGE), protein kinase C (PKC) activation, inflammation and endothelial dysfunction in 
patients with and without T2D2;53;74;75, all of which are involved in the pathogenesis of microvascular 
complications in T2D76. 
OSA and retinopathy 
During darkness, retinal oxygen demand increases and in the context of diabetes the retina cannot 
meet the added metabolic load imposed by the dark-adapted rod photoreceptors. This exacerbates 
retinal hypoxia and results in VEGF secretion, with the consequent development of diabetic 
retinopathy (DR)77. Hence, it is plausible that the presence of OSA, with recurrent nocturnal oxygen 
desaturations, might increase the burden of nocturnal hypoxia on the retina and might result in the 
development or progression of DR.  
OSA is not known to be associated with retinal changes similar to DR in patients without diabetes. 
However, OSA has been associated with several retinal and ocular manifestations. In one study an 
increase of respiratory disturbance index (RDI) from 0 to 10 was associated with a decrease in 
arteriole-to-venule ratio of 0.0178. Other retinal changes described in OSA included retinal arteriolar 
narrowing and venular widening or branch retinal vein occlusion79;80. 
In patients with T2D the relationship between OSA and DR is complex and the results of multiple 
studies were inconsistent; this is in part due to the poor methodology of some of the available 
literature. A recent systematic review found that out of 16 studies that examined the relationship 
between OSA and DR, 15 were cross-sectional in nature and 1 cohort study81, which highlights the 
need for more robust studies in this area. The above-mentioned systematic review showed that the 
cross-sectional associations between OSA and retinal microvascular changes were inconsistent, but 
there seems to be an association between OSA and more advanced DR such as pre-proliferative DR, 
proliferative DR and maculopathy81. 
Our own data (currently undergoing peer review) showed that OSA was associated with sight 
threatening DR and maculopathy, but not with background DR in a cross-sectional analysis. 
However, longitudinally we found that OSA was an independent predictor of the development of 
pre-/proliferative DR in patients withT2D after adjustment for confounders. 
So overall, the development of DR in its earlier stages seems to be dependent on the presence of 
diabetes, OSA appears to enhance progression of DR into sight threatening retinopathy through the 
development of pre-proliferative and proliferative changes. 
Whether CPAP has an impact on DR treatment and/or progression remains to be seen with several 
ongoing RCTs in this area. Our unpublished data showed that the progression to pre-proliferative or 
proliferative DR was less in OSA patients who were CPAP compliant compared with those who were 
not compliant. In an uncontrolled, hypothesis generating study, CPAP for 6 months was associated 
with improvement in visual acuity without an impact on macular oedema/thickness, suggesting 
improved functionality rather than actual change in the oedema82. Interestingly, the presence of 
OSA might affect the response to DR treatment as was shown by one study  in which poor response 
to anti-VEGF therapy with bevacizumab (Avastin) was associated with higher prevalence of OSA in 
patients with diabetic macular oedema and age-related macular degeneration83; whether CPAP can 
improve the response to DR treatment requires future studies. 
OSA and diabetes chronic kidney disease (CKD) 
In patients without diabetes, OSA has been associated with CKD in cross-sectional and longitudinal 
studies2;53;84;85. Small studies of short duration suggested potential beneficial effects of CPAP on 
albuminuria and renal function86-89.  In patients with T2D,a cross-sectional study of Japanese 
patients, ODI ≥ 5 was independently associated with microalbuminuria in women but not in men 
after adjustment for confounders90. In another cross-sectional study from the UK, OSA was 
associated with CKD in patients with T2D (adjusted OR 2.64, 95%CI 1.13-6.16, p=0.02)91. 
Longitudinally, OSA was associated with greater decline in eGFR compared to patients without OSA. 
Moreover, OSA was an independent predictor of study-end eGFR and eGFR decline after adjustment 
for potential confunders91. The impact of CPAP on CKD in patients with diabetes is unclear, but in a 
longitudinal study eGFR decline was lowered in patients with OSA who were compliant with CPAP91; 
ongoing RCTs will help to answer this point. 
OSA and peripheral neuropathy 
In patients without diabetes, OSA and nocturnal hypoxia were associated with peripheral 
neuropathy (based on nerve conduction studies) independent of age and obesity92;93. Moreover, one 
small study demonstrated that OSA was associated with axonal dysfunction and that 6 months of 
CPAP improved the amplitude of action potnetials94. Data in patients with T2D is limited with one 
cross-sectional study showing that OSA was associated with foot insensitivity and clinically evident 
diabetic peripheral neuropathy, independent of potential confounders95. In addition, OSA was 
independently associated with lower intra-epidermal nerve fibre density (based on skin biopsies) in 
patients with T2D compared to those without OSA75. Furthermore, patients with OSA were more 
likely to have a history of foot ulceration75 and one case series suggested that CPAP might aid the 
healing of foot ulceration in patients with diabetes96. 
OSA and other diabetes-related outcomes 
OSA has been associated with worse quality of life and erectile dysfunction which can be improved 
by CPAP, but data in patients with T2D are lacking10. 
Summary and conclusions 
OSA is a common condition and is associated with EDS, road traffic accidents, hypertension, worse 
glycaemic control, hypertension, CVD, diabetes-related microvascular complications, erectile 
dysfunction, impaired quality of life and increased mortality. CPAP treatment improves EDS and 
other OSA-related symptoms, has favourable impact on BP and lowers the risk of road traffic 
accidents but there is currently no evidence from RCTs that CPAP can lower CVD or mortality.  
OSA is very common in patients with T2D. The impact of OSA and CPAP in patients with T2D is still 
unclear with most studies having a cross-sectional nature. The limited number of longitudinal studies 
suggest that OSA is associated with hypertension, CVD, advanced DR, and CKD in patients with T2D. 
Most RCTs of OSA in the context of T2D were focussed on glycaemic control and the results are 
conflicting, but ongoing RCTs are assessing the impact of CPAP on other diabetes-related outcomes.  
While the impact of OSA and its treatment in patients with T2D remains to be fully explored, it is 
important to consider OSA in patients who have OSA-related symptoms such as EDS as CPAP 
treatment can improve symptoms. In addition, considering the increased risk of road traffic 
accidents in some patients with T2D, it is important to consider the contribution of OSA to this risk 
as CPAP might have a beneficial impact in this context. How to screen, the frequency of screening 
and the cost-effectiveness for screening for OSA in patients with T2D are questions that remain to be 
answered. 
  
 
 
 
 
Table 1: Summary of the evidence regarding the relationships between OSA and diabetes-related 
macro- and micro- vascular complications and the impact of CPAP. T2D: Type 2 diabetes; RCT: 
Randomised controlled trial; 
 Relationship with OSA Impact of CPAP 
 In patients 
without T2D 
In Patients with T2D In patients 
without T2D 
In patients 
with T2D 
Hypertension Observational 
cross-sectional 
and longitudinal 
studies and 
interventional 
trials 
Limited but similar 
to patients without 
T2D 
Favourable 
impact based 
on multiple 
RCTs 
Favourable 
impact based 
on limited 
RCTs 
Cardiovascular 
Disease 
Observational 
cross-sectional 
and longitudinal 
studies  
Observational cross-
sectional study 
showed an 
association with 
Stroke. 
Longitudinal 
observational study 
showed association 
with the 
development of 
coronary artery 
disease and heart 
failure 
Observational 
studies showing 
favourable 
impact of CPAP. 
No RCTs 
Unknnown 
Mortality Observational 
longitudinal 
studies 
Unknown Observational 
studies 
Unknown 
Chronic Kidney 
Disease 
Observational 
cross-sectional 
and longitudinal 
studies 
Mostly 
observational cross-
sectional studies 
and limited 
Favourable 
impact on 
albuminuria 
and renal 
One 
observational 
study suggest 
favourable 
longitudinal studies function mainly 
from limited 
non-
randomised 
trials and 1 pilot 
RCT 
impact on 
renal 
function 
Peripheral 
Neuropathy 
Observational 
cross-sectional 
studies and 
limited 
longitudinal 
studies and non-
randomised 
interventional 
trial 
Observational cross-
sectional study 
Favourable 
impact based 
on a non-
randomised 
trial 
Unknown 
Retinopathy None available Observational cross-
sectional and 1 
longitudinal study 
None available Observational 
study and a 
non-
randomised 
trial showed 
favourable 
impact 
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